지단백질 검사 시장 : 전략적 인사이트 및 예측(2026-2031년)

The Lipoprotein Testing Market is forecast to grow at a CAGR of 8.7%, reaching USD 17.89 billion in 2031 from USD 8.44 billion in 2026.

The global lipoprotein testing market is undergoing significant evolution, driven by the growing recognition of advanced lipid biomarkers in cardiovascular risk assessment. This market comprises diagnostic assays, laboratory instruments, reagents, and analytical platforms designed to evaluate lipoprotein-associated biomarkers involved in lipid metabolism and cardiovascular disease. The market includes testing for lipoprotein(a), apolipoprotein A-I, apolipoprotein B, lipoprotein particle distribution, and advanced lipoprotein subclasses that complement conventional lipid profile measurements. Demand continues increasing because cardiovascular disease remains the leading cause of mortality worldwide, while conventional lipid measurements alone cannot explain all cardiovascular events. Physicians are requesting advanced lipoprotein testing for patients with unexplained cardiovascular disease, strong family history, inherited dyslipidemias, and persistent cardiovascular risk despite statin therapy. Regulatory organizations and professional societies are recognizing the clinical importance of selected lipoprotein biomarkers, with updated guidelines increasingly recommending lipoprotein(a) measurement. Diagnostic manufacturers are responding by expanding standardized assay availability, improving automation, and enhancing analytical consistency across laboratory platforms. The strategic significance of the market continues increasing alongside the development of novel lipid-lowering therapies targeting lipoprotein(a), creating a strong link between diagnostics and therapeutics.

Market Drivers

Growing Clinical Recognition of Lipoprotein(a) as a Cardiovascular Risk Biomarker

• Lipoprotein(a) testing is becoming an important component of cardiovascular risk assessment because elevated concentrations independently increase the likelihood of atherosclerotic cardiovascular disease and calcific aortic valve disease. Cardiologists are incorporating Lp(a) measurements into routine evaluation for patients with premature cardiovascular disease and inherited lipid disorders. Traditional lipid measurements do not fully identify genetically determined cardiovascular risk, creating demand for complementary biomarkers that improve patient stratification. Diagnostic laboratories are therefore expanding standardized Lp(a) assay availability to support evolving clinical practice. Greater physician awareness strengthens long-term utilization across preventive cardiology.

Expansion of Precision Cardiovascular Medicine

• Precision medicine increasingly relies on biomarker-guided therapeutic decisions rather than uniform treatment strategies. Healthcare providers are requesting comprehensive lipoprotein profiling because individualized cardiovascular risk varies significantly among patients with similar cholesterol levels. Pharmaceutical companies are developing therapies targeting specific lipoprotein pathways, increasing dependence on accurate laboratory testing for patient identification and monitoring. This integration between diagnostics and therapeutics supports sustained market expansion while improving personalized disease management.

Increasing Burden of Cardiovascular Disease

• Cardiovascular disease remains a major global public health challenge and continues driving demand for improved diagnostic approaches. Healthcare systems are emphasizing earlier identification of high-risk individuals to reduce long-term disease burden and healthcare expenditures. Conventional lipid screening identifies many patients at risk but does not capture residual cardiovascular risk associated with inherited lipoprotein abnormalities. Advanced lipoprotein testing therefore provides additional clinical value by supporting earlier intervention and targeted prevention strategies.

Technological Advancements in Lipoprotein Analysis

• Modern analytical technologies improve the precision and reproducibility of advanced lipid testing. Diagnostic manufacturers are introducing highly automated immunoassays, NMR-based particle analysis, and high-sensitivity laboratory platforms that reduce variability between laboratories. Improved workflow efficiency enables higher testing volumes without compromising analytical quality. Continued innovation strengthens laboratory confidence while supporting broader clinical implementation.

Market Restraints

• Limited reimbursement for advanced lipoprotein testing restricts routine adoption in several healthcare systems despite growing clinical evidence. Lack of universal assay standardization for certain advanced lipoprotein biomarkers creates variability in result interpretation across laboratories. Physician awareness remains inconsistent outside specialized cardiology practice, limiting testing utilization among general healthcare providers. Additionally, the complexity of interpreting advanced lipoprotein profiles can present challenges for some clinicians.

Technology and Segment Insights

By Test Type

• Lipoprotein(a) testing represents the fastest-growing segment because elevated Lp(a) concentrations are increasingly recognized as genetically determined risk factors for atherosclerotic cardiovascular disease and calcific aortic valve disease. Updated clinical guidelines are encouraging physicians to measure Lp(a) at least once in adulthood, particularly for patients with premature cardiovascular disease or strong family history. Laboratories are expanding standardized immunoassays to accommodate growing testing demand. Conventional lipid testing (HDL, LDL, total cholesterol, triglycerides) remains the foundation of cardiovascular risk assessment. Apolipoprotein testing provides additional insights into atherogenic particle concentration. Lipoprotein particle testing offers advanced characterization of lipid-related cardiovascular risk.

By Technology

• Immunoassays dominate the market because they provide standardized, automated, and high-throughput measurement of lipoprotein biomarkers suitable for routine clinical laboratories. Diagnostic manufacturers continue improving assay sensitivity and reproducibility while integrating testing into automated chemistry analyzers. Enzymatic assays are widely used for routine lipid panel testing. Nuclear Magnetic Resonance (NMR) spectroscopy enables detailed lipoprotein particle analysis. Electrophoresis and chromatography-based methods provide specialized characterization for research and advanced clinical applications.

By End User

• Hospitals account for a significant share of lipoprotein testing because they manage patients with established cardiovascular disease, inherited lipid disorders, and multiple cardiometabolic risk factors. Diagnostic laboratories are expanding advanced lipid testing capabilities to support preventive cardiology and precision medicine. Academic and research institutes contribute to biomarker discovery and clinical validation. Specialty cardiology clinics are increasingly utilizing advanced lipoprotein testing for high-risk patient management. Ambulatory care centers are adopting testing for preventive health programs.

Competitive and Strategic Outlook

• The competitive landscape features major diagnostic companies with strong clinical chemistry and immunodiagnostics portfolios. F. Hoffmann-La Roche Ltd. differentiates itself through its integrated diagnostics ecosystem combining clinical chemistry, immunodiagnostics, and digital laboratory solutions, leveraging its cobas analyzer portfolio. Abbott Laboratories maintains a strong presence through its Alinity and ARCHITECT platforms, focusing on automation and standardized analytical performance. Siemens Healthineers AG offers a comprehensive portfolio of clinical chemistry and immunoassay solutions, including the Atellica laboratory platform. Danaher Corporation (Beckman Coulter Diagnostics) provides automated clinical chemistry systems used extensively in hospital and reference laboratories. Thermo Fisher Scientific Inc. supports cardiovascular diagnostics through its life science technologies and analytical instrumentation. Randox Laboratories specializes in multiplex biomarker testing, including cardiovascular assays. Quest Diagnostics and Labcorp are major independent laboratory providers offering advanced lipoprotein testing services.
• Strategic developments include increasing integration of automation and digital platforms, expansion of standardized Lp(a) assays, and preparation for companion diagnostic applications with emerging lipid-lowering therapies. Companies are forming collaborations with pharmaceutical developers and healthcare providers to support therapeutic development and clinical adoption. Product launches focus on high-throughput immunoassays, NMR-based particle analysis, and integrated laboratory solutions. Companies that successfully combine analytical excellence, regulatory compliance, and global laboratory support are expected to maintain competitive leadership.

Conclusion

• The lipoprotein testing market is poised for significant growth, driven by the growing clinical recognition of lipoprotein(a) and other advanced biomarkers in cardiovascular risk assessment. The transition from conventional lipid profiling toward comprehensive risk stratification supported by advanced biomarkers and precision medicine is reshaping the market. Companies that successfully deliver standardized, automated, and clinically validated testing solutions are expected to lead the market. Ongoing therapeutic innovation, regulatory support, and expanding preventive healthcare initiatives will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Lipoprotein Testing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Analysis (2021-2025)
• 3.6 Market Forecast (2026-2031)
• 3.7 Lipoprotein Testing Workflow Analysis
• 3.8 Cardiovascular Risk Assessment Landscape
• 3.9 Laboratory & Point-of-Care Testing Adoption Analysis
• 3.10 Preventive Healthcare & Population Screening Trends
• 3.11 Advanced Lipid Biomarker Testing Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Diagnostic Ecosystem Analysis
• 5.4 Reimbursement & Healthcare Coverage Analysis

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Advanced Lipoprotein Particle Analysis
• 6.3 Artificial Intelligence in Cardiovascular Risk Assessment
• 6.4 Automation in Clinical Laboratory Diagnostics
• 6.5 Point-of-Care Lipoprotein Testing Innovations
• 6.6 Digital Health & Remote Cardiovascular Monitoring

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Laboratory Accreditation Standards
• 7.3 Diagnostic Quality & Clinical Practice Guidelines

8. Lipoprotein Testing Market Landscape Analysis

• 8.1 Analysis by Test Type
• 8.2 Analysis by Technology
• 8.3 Analysis by End User

9. Lipoprotein Testing Market Segment Analysis (2021-2031)

• 9.1 By Test Type
  • 9.1.1 HDL Cholesterol Testing
  • 9.1.2 LDL Cholesterol Testing
  • 9.1.3 Total Cholesterol Testing
  • 9.1.4 Triglyceride Testing
  • 9.1.5 Lipoprotein (a) [Lp(a)] Testing
  • 9.1.6 Apolipoprotein Testing
  • 9.1.7 Lipoprotein Particle Testing
• 9.2 By Technology
  • 9.2.1 Immunoassays
  • 9.2.2 Enzymatic Assays
  • 9.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy
  • 9.2.4 Electrophoresis
  • 9.2.5 Chromatography-Based Methods
• 9.3 By End User
  • 9.3.1 Hospitals
  • 9.3.2 Diagnostic Laboratories
  • 9.3.3 Academic & Research Institutes
  • 9.3.4 Specialty Cardiology Clinics
  • 9.3.5 Ambulatory Care Centers

10. Lipoprotein Testing Market Geographical Analysis (2021-2031)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Lipoprotein Testing Market Country Analysis (2021-2031)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Switzerland
• 11.10 China
• 11.11 Japan
• 11.12 India
• 11.13 South Korea
• 11.14 Australia
• 11.15 Brazil
• 11.16 Saudi Arabia
• 11.17 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches & Technology Advancements

13. Company Profiles

• 13.1 Abbott Laboratories
• 13.2 F. Hoffmann-La Roche Ltd.
• 13.3 Siemens Healthineers AG
• 13.4 Beckman Coulter, Inc. (Danaher Corporation)
• 13.5 Thermo Fisher Scientific Inc.
• 13.6 Randox Laboratories Ltd.
• 13.7 QuidelOrtho Corporation
• 13.8 DiaSys Diagnostic Systems GmbH
• 13.9 SEKISUI Diagnostics, LLC
• 13.10 Diazyme Laboratories, Inc.
• 13.11 Tosoh Corporation
• 13.12 Mindray Medical International Limited
• 13.13 Sysmex Corporation
• 13.14 HORIBA, Ltd.
• 13.15 Boston Heart Diagnostics Corporation

14. Lipoprotein Testing Market Commercial Forecast Analysis

• 14.1 Conventional Lipid Profile Testing
• 14.2 Lipoprotein (a) [Lp(a)] Testing
• 14.3 Advanced Lipoprotein Particle Testing
• 14.4 Apolipoprotein Testing Services
• 14.5 Point-of-Care Lipoprotein Testing Solutions
• 14.6 Automated Laboratory Lipoprotein Testing Systems
• 14.7 AI-Enabled Cardiovascular Risk Assessment Platforms

15. Investment & Funding Analysis

• 15.1 Investments in Cardiovascular Diagnostics
• 15.2 Government Funding for Preventive Screening Programs
• 15.3 Research & Development Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends